Concepedia

Jay Tuttle

JT

Statistics

Publications

23

Citations

1.6K

H-Index

19

Active since

1994

Affiliations

Eli Lilly (United States)(Current)

Indiana University – Purdue University Indianapolis

University of California San Diego

Western University

Amsterdam University Medical Centers

Jay Tuttle is an author at Eli Lilly (United States) specializing in medicine, inflammatory bowel disease therapy, and immunotherapy.

ORCID

Publications per year

1994–2023

23

Publications

23

Shear level influences resistance artery remodeling: wall dimensions, cell density, and eNOS expression

Jay Tuttle, Ryan Nachreiner, Amardip S. Bhuller et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2001 · 245 citations

, , +14

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

William J. Sandborn, Marc Ferrante, Bal Raj Bhandari et al. · Gastroenterology · 2019 · 221 citations · Full text

, , +17

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen, Ajay Nirula, Mark J. Mulligan et al. · JAMA · 2021 · 208 citations · Full text

, , +10

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease

Bruce E. Sands, Laurent Peyrin‐Biroulet, Jarosław Kierkuś et al. · Gastroenterology · 2021 · 149 citations · Full text

, , +12

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

Jay Tuttle, Edit Drescher, Jesus Abraham Simón Campos et al. · New England Journal of Medicine · 2023 · 126 citations

, , +17

1–5 of 23